16 completed, 3 unknown, 3 withdrawn, 1 terminated. 23 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 16, Unknown 3, Withdrawn 3, Terminated 1 |
| Phase 1 | 5 | Completed 2, Unknown 2, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Primary Biliary Cirrhosis: new trials by email Literature Review of Primary Biliary Cirrhosis trials Research Report on Primary Biliary Cirrhosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis HTD1801 (BUDCA) - Primary Biliary Cholangitis, Primary Biliary Cirrhosis | Phase 2 | Completed | HighTide Therapeutics (Hong Kong) Limited | 24 | 2021-05-27 | 2026-08-25 |
| A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) TQA3526, Placebo to match TQA3526 - Primary Biliary Cirrhosis | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 130 | 2020-03-20 | 2020-02-20 |
| Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 20 | 2019-08-10 | 2024-06-06 |
| Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet - Primary Biliary Cirrhosis | Phase 2 | Completed | Zydus Therapeutics Inc. | 37 | 2017-08-18 | 2024-09-19 |
| Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. GKT137831, Placebo oral capsule - Primary Biliary Cirrhosis | Phase 2 | Completed | Calliditas Therapeutics AB | 111 | 2017-06-26 | 2022-06-29 |
| Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule - Primary Biliary Cirrhosis | Phase 2 | Completed | Gilead Sciences | 119 | 2016-11-28 | 2022-07-14 |
| Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA Fenofibrate, UDCA - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Withdrawn | Beijing 302 Hospital | 2016-01-01 | 2021-09-17 | |
| An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis LUM001 - Primary Biliary Cirrhosis | Phase 2 | Withdrawn | Mirum Pharmaceuticals, Inc. | 2015-05-01 | 2019-03-19 | |
| Pilot Study of FFP104 Dose Escalation in PBC Subjects FFP104 - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Unknown | Fast Forward Pharmaceuticals | 24 | 2015-05-01 | 2016-08-24 |
| Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis NGM282 - Primary Biliary Cirrhosis | Phase 2 | Completed | NGM Biopharmaceuticals, Inc | 36 | 2014-05-01 | 2017-03-28 |
| Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis NGM282, Placebo - Primary Biliary Cirrhosis | Phase 2 | Completed | NGM Biopharmaceuticals, Inc | 45 | 2014-02-01 | 2017-03-28 |
| Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis Obeticholic Acid - Primary Biliary Cirrhosis | Phase 2 | Completed | Intercept Pharmaceuticals | 27 | 2013-12-03 | 2022-08-24 |
| Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis LUM001, Placebo, Ursodeoxycholic Acid - PBC, Primary Biliary Cirrhosis | Phase 2 | Completed | Mirum Pharmaceuticals, Inc. | 66 | 2013-08-01 | 2019-03-27 |
| B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis Rituximab, Placebo - Fatigue, Primary Biliary Cirrhosis | Phase 2 | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | 71 | 2012-10-01 | 2017-01-13 |
| Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis conventional plus UC-MSC treatment, Conventional plus placebo treatment - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 100 | 2011-10-01 | 2013-05-31 |
| A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg - Primary Biliary Cirrhosis | Phase 2 | Completed | Janssen Research & Development, LLC | 20 | 2011-09-01 | 2016-06-20 |
| Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis fenofibrate, placebo - Primary Biliary Cirrhosis | Phase 2 | Withdrawn | University of Miami | 2011-04-01 | 2014-04-02 | |
| Pentoxifylline for Primary Biliary Cirrhosis Pentoxifylline - Primary Biliary Cirrhosis | Phase 2 | Completed | The Cleveland Clinic | 20 | 2010-11-01 | 2013-12-09 |
| Use of Fenofibrate for Primary Biliary Cirrhosis Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) - Primary Biliary Cirrhosis | Phase 2 | Completed | University of Florida | 20 | 2007-08-01 | 2018-03-08 |
| Initial Study of Rituximab to Treat Primary Biliary Cirrhosis rituximab - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Completed | University of California, Davis | 6 | 2007-01-01 | 2017-07-02 |
Showing 20 of 23. Sign in to see all of them.
Liver Cirrhosis, Biliary (23) · Biliary Atresia (1) · Biliary Tract Diseases (1) · Cholangitis (1) · Cholestasis (1) · Fatigue (1) · Inflammation (1) · Liver Cirrhosis (1)
Bile Duct Diseases (23) · Cholestasis, Intrahepatic (23) · Digestive System Diseases (23) · Fibrosis (23) · Liver Diseases (23) · Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Biliary Tract Diseases (22) · Cholestasis (22) · Liver Cirrhosis (22) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Abnormalities (1) · Signs and Symptoms (1)
Fenofibrate (2) · Rituximab (2) · Ursodeoxycholic Acid (2) · aldafermin (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · Congresses as Topic (1) · Pentoxifylline (1) · Transplantation (1) · Ustekinumab (1) · lamivudine, zidovudine drug combination (1) · moexipril (1) · obeticholic acid (1) · saroglitazar (1) · seladelpar (1) · setanaxib (1)
Beijing 302 Hospital (2) · Mirum Pharmaceuticals, Inc. (2) · NGM Biopharmaceuticals, Inc (2) · Calliditas Therapeutics AB (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Fast Forward Pharmaceuticals (1) · Gilead Sciences (1) · HighTide Therapeutics (Hong Kong) Limited (1) · Intercept Pharmaceuticals (1) · Janssen Research & Development, LLC (1) · Light Chain Bioscience - Novimmune SA (1) · Mayo Clinic (1) · Newcastle-upon-Tyne Hospitals NHS Trust (1) · The Cleveland Clinic (1) · University of Alberta (1)
United States (16) · United Kingdom (8) · Canada (5) · China (3) · Australia (2) · Germany (2) · Italy (2) · Belgium (1) · Greece (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Spain (1) · Vietnam (1)
Cynthia Levy, MD (2) · Stephen J Rossi, PharmD (2) · Adrian DiBisceglie, MD (1) · Andrew L Mason, MBBS MRCPI (1) · Bruce Bacon, MD (1) · Catherine Vincent, MD FRCPC (1) · Christopher L Bowlus, MD (1) · Claudia O. Zein, MD, MSc (1) · David EJ Jones, BA, BM, MRCP, PhD, FRCP (1) · Deven Parmar, MD FACP FCP (1) · Fu-Sheng Wang, professor (1) · George Harb, MD (1) · James Neuberger, MD FRCP (1)
PMID 25543678, PMID 21083674, PMID 29790196, PMID 33769355, PMID 34487750, PMID 35367282, PMID 36809195, PMID 37183520, PMID 40907882
2014 (2), 2016 (1)